а

Anti-mCTLA-4 VHH (H11)



His tag: highlighted in blue Signal Sequence: highlighted in red

MKYLLPTAAAGLLLLAAQPAMAQVQLVESGGGLAQP GGSLRLSCAASGSTISSVAVGWYRQTPGNQREWVA TSSTSSTTATYADSVKGRFTISRDNAKNTIYLQMNSL KPEDTAVYYCKTGLTNWGRGTQVTVSSAAAHHHHH HHHHH

Molecular weight: 13.6 kDa



d С Anti-mCTLA-4 VHH (H11) Anti-serum albumin VHH Non-reduced Reduced VHH VHH kDa GS-linker His-tag 198 His tag: highlighted in blue 98 Signal Sequence: highlighted in red 62 Linker: highlighted in purple 49 38 METDTLLLWVLLLWVPGSTGQVQLVESGGGLAQPGGSL 28 RLSCAASGSTISSVAVGWYRQTPGNQREWVATSSTSSTT 17 14 ATYADSVKGRFTISRDNAKNTIYLQMNSLKPEDTAVYYCK TGLTNWGRGTQVTVSSGGSGGSGGSGGSGGSGGSGGSG 6 SGAVQLVESGGGLVQPGNSLRLSCAASGFTFRSFGMSW 4 **VRQAPGKEPEWVSSISGSGSDTLYADSVKGRFTISRDNA** KTTLYLQMNSLKPEDTAVYYCTIGGSLSRSSQGTQVTVS 5 2 5 **SAAAHHHHHHHHH**

Protein (µg)

2

Molecular weight: 27.2 kDa

Supplementary Fig. 1 Generation of anti-mouse CTLA-4 VHH (H11) and half-life extended H11 linked to anti-serum albumin VHH (H11-HLE). Amino acid sequence and SDS-PAGE of H11 (**a** and **b**) and H11-HLE (**c** and **d**)

а

Signal Sequence: highlighted in red

Ipilimumab mlgG2a heavy chain

MGWSCIILFLVATATGVHSQVQLVESGGGVVQPGRSLRLSCAAS GFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGT LVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTL TWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNV AHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKI KDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTH REDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTI SKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVE WTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSY SCSVVHEGLHNHHTTKSFSRTPGK

Ipilimumab mlgG2a light chain

MGWSCIILFLVATATGVHSEIVLTQSPGTLSLSPGERATLSCRASQ SVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTD FTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRADAAPTV SIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVL NSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPI VKSFNRNEC

Molecular weight: 146 kDa

С

Signal Sequence: highlighted in red Mutation in Fc region: highligyed in blue

Ipilimumab mlgG2a L234A_L235A_P329G heavy chain

MGWSCIILFLVATATGVHSQVQLVESGGGVVQPGRSLRLSCAAS GFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRF TISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGT LVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTL TWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNV AHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNAAGGPSVFIFPPKI KDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTH REDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLGAPIERTI SKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVE WTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSY SCSVVHEGLHNHHTTKSFSRTPGK

Ipilimumab mlgG2a L234A_L235A_P329G light chain MGWSCIILFLVATATGVHSEIVLTQSPGTLSLSPGERATLSCRASQ SVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTD FTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRADAAPTV SIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVL NSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPI VKSFNRNEC

Molecular weight: 146 kDa

Supplementary Fig. 2 Generation of Ipilimumab mIgG2a (Ipi-WT) and Ipilimumab mIgG2a LALAPG (Ipi-LALAPG). Amino acid sequence and SDS-PAGE of Ipi-WT (**a** and **b**) and Ipi-LALAPG (**c** and **d**)





d



Supplementary Fig. 3 Humanization of the Ctla4 gene via CRISPR/Cas9-mediated gene editing The targeting construct replaced the exons coding for the extracellular (exon 2) and part of transmembrane (exon 3) domains of murine CTLA-4 with those of human CTLA-4.